CTOs on the Move

Myovant

www.myovant.com

 
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.myovant.com
  • 2000 Sierra Point Parkway 9th Floor
    Brisbane, CA USA 94005
  • Phone: 650.238.0250

Executives

Name Title Contact Details

Similar Companies

Walter Payton Cancer Fund

Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ADF Engineering Inc

ADF Engineering Inc is a Miamisburg, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tropical Looks Day Spa

Tropical Looks Day Spa is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spero Therapeutics

Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.

Vysis

Vysis, Inc. is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.